Voxelotor

Voxelotor (GBT 440) is a potent inhibitor of haemoglobin S (HbS) polymerization. Voxelotor has the potential for sickle cell disease (SCD) treatment[1].

Product Specifications

CAS Number

[1446321-46-5]

Product Name Alternative

GBT 440

UNSPSC

12352005

Hazard Statement

H302, H312, H315, H319, H332, H335

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/GBT-440.html

Purity

99.99

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=CC=CC(OCC2=C(C3=CC=NN3C(C)C)N=CC=C2)=C1C=O

Molecular Formula

C19H19N3O3

Molecular Weight

337.37

Precautions

H302, H312, H315, H319, H332, H335

References & Citations

[1]Oksenberg D, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016 Oct;175 (1) :141-53.|[2]Metcalf B, Chuang C, Dufu K, et al. Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin. ACS Med Chem Lett. 2017;8 (3) :321-326.